Eosinophil and Monocyte Counts as Hematological Markers for Response to Tetracyclines for Treating Bullous Pemphigoid.
Aim: Tetracyclines are used in bullous pemphigoid (BP) treatment because of their anti-inflammatory properties. We investigated the effects of tetracyclines on blood cell counts, which serve as inflammatory markers, in patients with BP. Materials and Methods: The study included 50 patients with BP w...
| Publicado en: | Turkish Journal of Dermatology / Türk Dermatoloji Dergisi Vol. 18; no. 1; pp. 16 - 23 |
|---|---|
| Autores principales: | , , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Galenos Yayinevi Tic. LTD. STI
Jan-Mar2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177666171&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177666171 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 13077635 87WM jtl: Turkish Journal of Dermatology / Türk Dermatoloji Dergisi issn: 13077635 maglogo: N pubinfo: dt: Jan-Mar2024 vid: 18 iid: 1 pid: 28155 pub: Galenos Yayinevi Tic. LTD. STI artinfo: ui: 177666171 177666171 177666171 10.4274/tjd.galenos.2024.69775 177666171 ppf: 16 ppct: 7 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Eosinophil and Monocyte Counts as Hematological Markers for Response to Tetracyclines for Treating Bullous Pemphigoid. aug: au: Avcı, Ceylan Gürbüz, Özlem Akarsu, Sevgi Aktan, Şebnem sug: subj: Eosinophils Monocytes Biological Markers Blood Tetracyclines Therapeutic Use Pemphigoid, Bullous Drug Therapy Drug Efficacy Evaluation Antiinflammatory Agents Therapeutic Use Blood Cell Count Inflammation Human Treatment Duration Academic Medical Centers Comorbidity Pretest-Posttest Design Retrospective Design C-Reactive Protein Disease Remission Odds Ratio Descriptive Statistics Confidence Intervals Treatment Outcomes ab: Aim: Tetracyclines are used in bullous pemphigoid (BP) treatment because of their anti-inflammatory properties. We investigated the effects of tetracyclines on blood cell counts, which serve as inflammatory markers, in patients with BP. Materials and Methods: The study included 50 patients with BP who were treated with tetracycline group antibiotics and followed up for an average duration of 3.1±1.2 months in a university hospital between January 2013 and December 2022. Demographic data, comorbidities, medications, physical examination findings, treatment responses, and hematological parameters before and after treatment were retrospectively recorded. Results: The median blood eosinophil count (450 cells μL-1; range: 0-430) and the mean blood monocyte count (660 cells μL-1; range: 300-1100) of the 50 patients with BP were significantly higher than those of the healthy age- and gender-matched Turkish population (P < 0.001; P = 0.01; respectively). At the end of the follow-up period, 30 patients were in remission, whereas relapses occurred in 20 patients. The eosinophil and monocyte cell count, eosinophilto-lymphocyte ratio (ELR), and C-reactive protein (CRP) levels in patients who were in remission were significantly lower compared to those pre-treatment (P = 0.001, P = 0.02, P < 0.001, P = 0.001, respectively). There was no significant difference between the doxycycline and tetracycline treatment groups regarding the odds of remission after treatment [odds ratio: 2 (95% confidence interval: 0.5-7.3)]. Conclusion: Higher levels of circulating monocytes indicate their role in the pathogenesis of BP. Peripheral eosinophil count, ELR, and monocyte count, along with CRP, could serve as markers for monitoring the response to tetracyclines and the risk of relapse in patients with BP. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|